

Curriculum Vitae

Personal information **Catarina Santos**

Work experience

FEB2025/Current - Clinical Assessor at Infarmed - National Authority of Medicines and Health Products, Portugal (Clinical assessment of clinical trials and marketing authorisation procedures);

NOV2024/FEB2025 - General Physician at Unidade Local de Saúde da Guarda, Portugal (General medicine practice);

FEB2024/NOV2024 - Medical Manager at BlueClinical (Collaboration in phase I-IV clinical trials, providing medical input for study design, project feasibility, and regulatory documents, ensuring that are ethically acceptable, medically sound, and up-to-date);

SEP2021/NOV2024 - Research Physician at BlueClinical (Collaboration in early-phase clinical trials with healthy volunteers and special populations, providing comprehensive medical assessments and ensuring compliance with legal, ethical, and regulatory standards);

JUN2019/NOV2023 - Clinical Pharmacology Residency at Centro Hospitalar Universitário Lisboa Norte (Specialized training in Clinical Pharmacology, totaling of 48 months:

- Clinical Practice (19 months):
 - Internal Medicine (12 months, JUN2019/MAY2020).
 - Intensive Care (3 months, SEP2021/NOV2021).
 - Neurology Department - main areas: Multiple Sclerosis, Parkinson's and Migraine (4 months, OCT2020/DEC2020 and DEC2021).
- Clinical Trials and Research (14 months):
 - BlueClinical Ltd (6 months, MAR2021/AUG2021).
 - Academic Clinical Center of Braga (3 months, JUL2022/SEP2022).
 - Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E. - Early Phase Trials Unit and Outcomes Research Laboratory (5 months, OCT2022/DEC2022 and MAR2023/APR2023).
- Regulatory Affairs (6 months):
 - INFARMED - National Authority for Medicines and Health Products, I.P. (6 months, JAN2022-JUN2022) - Medicines Assessment, Medicines Risk Management and Health Technology Assessment departments.
- Basic Pharmacology and Toxicology (5 months):
 - Basic Pharmacology (3 months, JUN2020-AUG2020).
 - Toxicology (2 months, JAN2021/FEB2021).
- Pharmacokinetic and Therapeutic Consultancy (4 months):
 - Hospital pharmacy and Pharmacy and Therapeutics Committee at Centro Hospitalar Universitário Lisboa Norte (4 months, JAN2023/FEB2023 and MAY2023/JUN2023).

Education and training

- CLIC - Clinical Investigator Certificate, L2, NOVA Medical School (2024), Faculdade de Ciências Médicas;
- Last GCP training: GCP Good Clinical Practice, Refresher Training (2023), Allucent;
- Good Clinical Practice: ICH Good Clinical Practice E6 (R2) (2022), The Global Health Network, online;
- Principles of Clinical Pharmacology (2021-2022), National Institutes of Health, online;
- EATRIS-Plus Summer School in Personalised Medicine (2021), EATRIS-Plus Summer School Curriculum Committee (EATRIS C&S, EATRIS Portugal, EATRIS Slovenia), online;
- Advanced Studies Course in Clinical Research and Health Services (2020-2021), Faculdade de Medicina da Universidade do Porto, 53,0 ECTS, 1431 hours;
- Training Programme in Pharmaceutical Medicine and Clinical Research (2019-2020), 200hours, PMA - Pharmaceutical Medicine Academy, Lda and Secção Regional do Norte da Ordem dos Farmacêuticos;
- CLIC - Clinical Investigator Certificate L1, NOVA Medical School (2017), Faculdade de Ciências Médicas;
- Master's in medicine, Universidade da Beira Interior (2008-2014).

Additional information

Publications

- Santos C.D. (2024). Inibidores de checkpoint imunológico: complementaridade entre ensaios clínicos e farmacovigilância. Boletim de Farmacovigilância, 28(1/2);
- Santos, C.D., Fernandes, J., Avó-Baião, R., Prada, L. & Silva, M. (2023). Psychiatric adverse drug reactions in children: a review of reports to the Portuguese National Pharmacovigilance System. British Journal of Pharmacology, 180, 190. (abstract);
- Gonçalves J, Santos C.D., Fresco P & Fernandez-Llimos F. (2023). Potential use of reninangiotensin-aldosterone system inhibitors to reduce COVID-19 severity. Revista Portuguesa de Cardiologia, 42(4), 373-383;
- Santos C.D. (2022). Esclerose Múltipla: Importância da Farmacovigilância. Boletim de Farmacovigilância, 26(9/10);
- Avó-Baião, R., Fernandes, J.P., Santos, C.D., Martins, A.S. & Silva, M. (2022). Drug-Induced Liver Injury (DILI) and Ulipristal: A cautionary tale. Drug Safety 45, 1261-1262 (abstract);
- Prada L*, Santos C.D.*, Avó-Baião R, Costa J, Ferreira J.J. & Caldeira D. (2021). Risk of SARSCoV-2 Infection and

COVID-19 Severity Associated with Exposure to Nonsteroidal AntiInflammatory Drugs: Systematic Review and Meta-Analysis. Journal of Clinical Pharmacology, 61(12), 1521-1533. (*first authorship shared).

Projects

- 1st place in the "Pharmacovigilance: Involving the Citizen" poster competition, INFARMED I.P., (2023) - "Santos C.D., Fernandes, J., Prada, L., Avó-Baião, R. & Silva, M. (2023). Immune checkpoint inhibitors and cardiac events – a pharmacovigilance database analysis. Farmacovigilância: Envolver o Cidadão, INFARMED I.P., May 30, Lisbon, Portugal."
- 2nd place in the poster competition on "Pharmacovigilance Day", INFARMED I.P. (2022) - "Prada, L., Fernandes, J., Santos, C.D., Caldeira, D., Fernandes, M.R. & Silva, M. (2022). Adverse drug reactions of psychotropic drugs in children: a review of reports to the Portuguese National Pharmacovigilance System. Dia da Farmacovigilância, INFARMED I.P., December 13, Lisbon, Portugal."

Memberships

- Effective member of the Portuguese Society of Pharmacology (2024).
- Member number 57790 of the Portuguese Medical Association (2014).

Other Relevant Information